Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX [EXTENSION OF 700006658]

Trial Profile

Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX [EXTENSION OF 700006658]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Aug 2018 Results published in the Journal of Infectious Diseases.
    • 24 Mar 2016 Primary end points has been modified.
    • 16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top